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Abstract
Treating insulin resistance with pioglitazone normalizes renal function and improves small nerve fibre function and architecture; however, it
does not affect large myelinated nerve fibre function in mouse models of type 2 diabetes (T2DM), indicating that pioglitazone affects the body
in a tissue-specific manner. To identify distinct molecular pathways regulating diabetic peripheral neuropathy (DPN) and nephropathy (DN), as
well those affected by pioglitazone, we assessed DPN and DN gene transcript expression in control and diabetic mice with or without pioglita-
zone treatment. Differential expression analysis and self-organizing maps were then used in parallel to analyse transcriptome data. Differential
expression analysis showed that gene expression promoting cell death and the inflammatory response was reversed in the kidney glomeruli but
unchanged or exacerbated in sciatic nerve by pioglitazone. Self-organizing map analysis revealed that mitochondrial dysfunction was normalized
in kidney and nerve by treatment; however, conserved pathways were opposite in their directionality of regulation. Collectively, our data suggest
inflammation may drive large fibre dysfunction, while mitochondrial dysfunction may drive small fibre dysfunction in T2DM. Moreover, targeting
both of these pathways is likely to improve DN. This study supports growing evidence that systemic metabolic changes in T2DM are associated
with distinct tissue-specific metabolic reprogramming in kidney and nerve and that these changes play a critical role in DN and small fibre DPN
pathogenesis. These data also highlight the potential dangers of a ‘one size fits all’ approach to T2DM therapeutics, as the same drug may
simultaneously alleviate one complication while exacerbating another.
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Introduction
Type 2 diabetes mellitus (T2DM) affects over 387 million people
worldwide [1], and its prevalence continues to increase [2]. T2DM
itself is a complex metabolic disease characterized by hypergly-
caemia, hyperlipidemia and impaired insulin signalling that develops
as a result of genetic factors, obesity or the environment. As T2DM
progresses, oxidative stress, high circulating blood glucose levels
and hyperlipidemia can promote microvascular complications that
can result in severe debility and increased mortality. These complica-
tions are one of the greatest challenges facing the healthcare industry:
in 2014 alone, the global medical expenditure for diabetic patients
totalled over $245 billion, with 25–45% of those costs related to
associated vascular complications [3].
The most common of these microvascular complications includes
diabetic peripheral neuropathy (DPN) and diabetic nephropathy (DN)
[4, 5]. DPN affects 50% of diabetic patients and is characterized by
progressive loss of sensation in the limbs, pain and allodynia. DPN
progression also increases the risk of infection and foot ulcers that
can lead to amputation of the affected limb [6]. There is no cure for
DPN, and treatments are limited to glycemic control and symptomatic
relief [4]. Similarly, DN affects approximately 40% of diabetic
patients. Marked by albuminuria and impaired glomerular filtration,
DN is the leading cause of end-stage renal disease in the United
states [7] and is primarily responsible for the increased mortality in
T2DM [8]. Thus, there is a critical need for effective therapeutics and
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a better understanding of the mechanisms underlying T2DM compli-
cations.
Pioglitazone is a drug that is often prescribed to treat T2DM [9,
10]. In T2DM animal models, pioglitazone ameliorates DN and dia-
betic retinopathy via multiple pathways [9, 11–16] and can attenuate
neuropathic pain and nervous system inflammation [17, 18]. Mecha-
nistically, pioglitazone acts as an agonist of peroxisome proliferator-
activated receptor gamma (PPARG), but it differentially regulates
metabolism in a tissue-specific manner [19]. We recently reported
that pioglitazone normalized the renal function and significantly
improved small nerve fibre function in the C57BLKS-db/db murine
model of T2DM [20]. However, pioglitazone had no effect on the phe-
notypical measurement of large myelinated fibre function.
In this study, we expand on our previous findings by evaluating gene
expression changes in both the nerve and kidney from control (db/+),
diabetic (db/db) and pioglitazone-treated (db/+ PIO and db/db PIO) mice
using RNA-sequencing (RNA-Seq); we subsequently analyse these
changes using both differential analysis [20] and self-organizing maps
(SOMs) [21–23]. This combination of analyses, tissues and treatment
represents several important advances over previous studies examining
diabetes and pioglitazone. First, RNA-Seq provides more complete
transcriptomic information than microarray analysis and is much more
sensitive and specific [24]. Second, we expand our tissue analysis to
include the kidney which provides key information into the mechanisms
of DN as well as pioglitazone treatment. Third, the simultaneous analysis
and subsequent comparison of both nervous and renal tissue allows us
to assess the tissue-specific effects of pioglitazone as well as the basic
mechanisms underlying diabetic complications in peripheral tissue.
Finally, the parallel use of two forms of RNA-Seq analysis will alleviate
the wide variety of results that can be generated using common software
packages [25, 26].
Materials and methods
Animals
Male C57BLKS (BKS) db/+ and db/db mice (BKS.Cg-m+/+Leprdb/J;
stock number 000642; Jackson Laboratory, Bar Harbor, ME) were fed a
standard diet (AIN76A; 11.5% kcal fat; Research Diets, New Brunswick,
NJ, USA) and cared for in a pathogen-free environment by the Univer-
sity of Michigan Unit for Laboratory Animal Medicine. Mice were treated
with or without 15 mg/kg pioglitazone (112.5 mg pioglitazone/kg chow
for a dose of 15 mg/kg to the mouse) between 5 and 16 weeks of age,
for 11 total weeks (Fig. 1A). Animal protocols were approved by the
University of Michigan University Committee on Use and Care of Ani-
mals and complied with Diabetic Complications Consortium guidelines
(https://www.diacomp.org/shared/protocols.aspx).
Metabolic phenotyping
For each animal, bodyweight was recorded and fasting blood glucose
(FBG) levels were measured with an AlphaTrak Glucometer (Abbott Lab-
oratories, Abbott Park, IL, USA) weekly. Glycated haemoglobin (GHb)
levels were determined using a Glyco-Tek Affinity column (catalog no.
5351; Helena Laboratories, Beaumont, TX, USA) at the Michigan Dia-
betes Research and Training Center Chemistry Core. Fasting plasma
Fig. 1 Study workflow. (A) db/+ and db/db mice were treated with or
without 15 mg/kg pioglitazone (112.5 mg pioglitazone/kg chow, for a
final dose of 15 mg/kg to the mouse) from 5 to 16 week of age. (B)
Total RNA from nerve and kidney tissues was isolated for RNA-Seq
analysis. RNA-Seq data were mapped, aligned and used for differential
expression and self-organizing map analysis. The identified genes of
interest were used for functional enrichment analysis. SCN, sciatic
nerve; DRG, dorsal root ganglia; Glom, glomeruli; QA, quality assess-
ment.
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insulin, total cholesterol and total triglycerides were measured by the
National Mouse Metabolic Phenotyping Center (Vanderbilt University,
Nashville, TN, USA).
DPN and DN phenotyping
All animals were phenotyped for DPN and DN according to Diabetic
Complications Consortium guidelines [27, 28]. Motor (sciatic) and sen-
sory (sural) nerve conduction velocities (NCVs) were measured for large
nerve fibre function, and hind paw withdrawal latency from a thermal
stimulus was measured for small fibre function using our published
protocols [29, 30]. The periodic acid–Schiff (PAS) staining on 3-lm-
thick fixed kidney slices determined mesangial area as previously
described [31, 32]. Urinary albumin levels, albumin/creatinine ratios,
glomerular area and glomerular PAS-positive area were measured using
our published protocols [31,32].
RNA-Seq
To identify mechanisms affected by pioglitazone in DPN and DN at the
transcriptomic level, we analysed steady-state gene expression using
RNA-Seq (Fig. 1B). Total RNA was isolated from sciatic nerve (SCN),
dorsal root ganglia (DRG), and kidney glomeruli (Glom) and cortex from
db/+ (n = 6), db/db (n = 6), db/+ PIO (n = 6), and db/db PIO (n = 6)
mice. RNA quality was assessed using TapeStation (Agilent, Santa
Clara, CA). Samples with RNA integrity numbers ≥8 were prepared
using the Illumina TruSeq mRNA Sample Prep v2 kit (Catalog #s RS-
122-2001, RS-122-2002; Illumina, San Diego, CA, USA). Multiplex
amplification was used to prepare cDNA with a paired-end read length
of 100 bases using an Illumina HiSeq 2000 (Illumina, Inc., San Diego,
CA, USA). RNA-sequencing was performed by the University of Michi-
gan DNA Sequencing Core (http://seqcore.brcf.med.umich.edu/).
Quality control assessment of RNA-Seq data was completed using
the FastQC tool (http://www.bioinformatics.babraham.ac.uk/projects/fa
stqc/) for high throughput sequencing before and after RNA-Seq align-
ment. Then, RNA-Seq data were analysed using the Tuxedo suite of
sequence analysis programs, including Bowtie, TopHat and Cufflinks
[33]. Using TopHat, the resulting FASTQ files were aligned to the NCBI
reference mouse transcriptome (NCBI 37) to identify known transcripts.
Mapped reads were processed using the Cufflinks algorithm to calculate
fragments per kilobase of exon per million mapped reads (FPKM),
which accurately reflects the RNA transcript number normalized for
RNA length and total number of mapped reads [33].
Differential expression analysis
The output of Cufflinks was loaded into Cuffdiff [33] to quantify differ-
ences in expression of combined transcripts for each gene between the
groups within each tissue (db/+ versus db/db, db/+ versus db/+ PIO,
db/+ PIO versus db/db PIO, and db/db versus db/db PIO). The differen-
tially expressed genes (DEGs) with a false discovery rate (FDR) cut-off
of <0.05 were identified between groups, and sets were compared
within and across tissues to identify gene expression changes. Analyses
focused on db/+ versus db/db and db/db versus db/db PIO DEG sets to
identify gene expression changes in db/db mice that were reversed,
exacerbated or unaffected by pioglitazone treatment.
SOM analysis
SOM analysis was performed to identify gene clusters with similar
expression patterns in kidney and nerve of db/+, db/db and db/db PIO
mice. SOMs generate a two-dimensional grid and cluster similar pat-
terns of data points into units called modules. FPKM were pre-pro-
cessed by removing genes with expression values less than log23 and
were centred at zero for each gene [34]. Pre-processed FPKM were
applied to a SOM using the algorithm implemented in the MATLAB soft-
ware Neural Networking Toolbox [www.mathworks.com]. Gene sets
having a similar expression pattern were grouped into modules. Each
module in the SOM panel was subjected to functional enrichment analy-
sis. Adjacent modules were further combined into clusters that share
enriched functions of interest and similar gene expression patterns.
Function and pathway enrichment analysis
Over-represented biological functions from the DEG sets and SOM mod-
ules were identified by functional enrichment analysis using the Data-
base for Annotation, Visualization and Integrated Discovery (DAVID 6.7)
(http://david.abcc.ncifcrf.gov). Gene Ontology terms and Kyoto Encyclo-
pedia of Genes and Genomes pathways were adopted as the functional
terms [35]. A Benjamini–Hochberg corrected P-value <0.05 was used to
identify significantly over-represented biological functions in the DEG
sets. To visualize results, heat maps were generated using the most
over-represented biological functions for DEG sets of interest. Hierarchi-
cal clustering based on significance values was used to represent over-
all similarity and differences between the DEG sets [36]. Moreover,
clusters from SOM analysis were investigated to identify canonical path-
ways using Ingenuity Pathway Analysis software (IPA, www.qiagen.
com/ingenuity). A Benjamini–Hochberg adjusted P-value was calculated
using the Fisher’s exact test and <0.05 used to identify significantly
over-represented canonical pathways.
RNA-Seq qPCR validation
Technical validation of RNA-Seq data was performed on glomerular tis-
sue by quantitative real-time polymerase chain reaction (RT-qPCR;
n = 6/group). Biological confirmation was performed on glomerular and
SCN tissue (n = 6/group). We focused on the SOM cluster, containing
genes regulated by diabetes, but reversed by pioglitazone treatment in
both kidney glomeruli and SCN (Table 1; Fig. 4) as this cluster likely
represents pathways that may drive both DN and small nerve fibre dys-
function and provides insight into conserved pathways in the diabetic
kidney and nerve. Our selection of specific genes for RT-qPCR was
based on a combination of expression level (FPKM), fold-change, FDR
significance, P-values (Data S1). Based on our understanding of mito-
chondrial substrate metabolism in complications-prone tissue [37–39],
and the established role of oxidative stress in diabetic complications
[40], we chose two targets encoding components of fatty acid b-oxida-
tion (Acaa2, and Echs1 encoding the second and last enzymes of b-oxi-
dation) for technical validation, and two targets encoding subunits of
complex II and complex IV of the mitochondrial electron transport sys-
tem (Sdhb, complex II; Cox4i1, complex IV), and a target encoding a
mitochondrial peroxynitrite antioxidant enzyme, peroxiredoxin-5 (Prdx5)
for biological confirmation. cDNA was generated from 40 ng of total
RNA (iScript cDNA Synthesis Kit; Bio-Rad, Hercules, CA). RT-qPCR was
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performed in triplicate using sequence-specific primers (Table S16),
Power SYBR Green PCR Master Mix (Applied Biosystems/Waltham,
MA, USA) and the StepOnePlusTM Real-Time PCR System (Applied
Biosystems/Waltham, MA, USA). Expression of each gene was calcu-
lated from a cDNA titration within each plate (standard curve method)
and normalized to the geometric mean of tyrosine 3-monooxygenase/
tryptophan 5-monooxygenase activation protein (Ywhaz) endogenous
reference gene expression. Samples were assayed in triplicate.
Statistical analyses of phenotypic data
Statistical analyses of phenotypic and RT-qPCR data utilized GraphPad
Prism Software, version 6 (GraphPad Software, La Jolla, CA, USA). Data
were assumed to follow a Gaussian distribution based on the rules for
transformation and non-normative data [41]. One-way ANOVA with
Tukey’s post-test for multiple comparisons or Kruskal–Wallis test with
Table 1 Pathway enrichment analysis of SOM Cluster. Top 20 significantly enriched canonical pathways among the shared genes in modules
42 and 49 from the SOM analysis using IPA*
Canonical pathways BH P-value* Genes
Mitochondrial dysfunction 7.94E20 Ndufa4, Sdhb, Cox7b, Cox6a1, Cox6c, Prdx5, Uqcr11, Xdh, Aco2, Ndufb3,
Ndufb10, Pdha1, Ndufb9, Ndufab1, Ndufb6, Aco1, Atp5 g3, Cox4i1,
Sdha, Ndufv1, Cox6b1, Ndufb4, Cycs, Ndufv3, Uqcrb, Gsr, Atp5b, Uqcr10,
Uqcrc2, Cyc1, Cox5a, Cox7a2, Ndufa12, Atpaf2, Uqcrq
Oxidative phosphorylation 7.94E20 Ndufa4, Sdhb, Cox7b, Cox6a1, Cox6c, Uqcr11, Ndufb3, Ndufb10, Ndufb9,
Ndufab1, Ndufb6, Atp5 g3, Cox4i1, Sdha, Ndufv1, Cox6b1, Ndufb4,
Cycs, Ndufv3, Uqcrb, Atp5b, Uqcr10, Uqcrc2, Cyc1, Cox5a, Cox7a2,
Ndufa12, Atpaf2, Uqcrq
TCA cycle II (Eukaryotic) 3.16E17 Sdha, Sdhb, Idh3 g, Aco2, Mdh1, Sucla2, Cs, Suclg1, Dlst, Dld, Idh3a,
Mdh2, Fh, Aco1, Idh3b
Glycolysis I 4.37E07 Pgk1, Eno1, Tpi1, Pgam1, Pkm, Aldoa, Gapdh, Pfkl, Aldoc
Glutaryl-CoA degradation 6.17E06 Hadhb, L3hypdh, Acat1, Ehhadh, Hsd17b4, Hadh
Gluconeogenesis I 6.17E06 Pgk1, Eno1, Pgam1, Aldoa, Gapdh, Mdh1, Mdh2, Aldoc
Valine degradation I 7.41E06 Hadhb, Echs1, Bcat2, Bckdha, Dld, Dbt, Ehhadh
Acetyl-CoA Biosynthesis I
(Pyruvate dehydrogenase complex)
8.71E06 Pdha1, Dlat, Dld, Dbt, Pdhb
Fatty acid b-oxidation I 2.00E05 Hadhb, Echs1, Ehhadh, Hsd17b4, Acadm, Acaa2, Eci1, Hadh
Isoleucine degradation I 2.14E05 Hadhb, Echs1, Bcat2, Acat1, Dld, Ehhadh
Tryptophan degradation III (eukaryotic) 2.19E04 Hadhb, L3hypdh, Acat1, Ehhadh, Hsd17b4, Hadh
Sucrose degradation V (Mammalian) 1.32E03 Tpi1, Aldoa, Galm, Aldoc
Branched-chain a-keto acid
dehydrogenase complex
1.70E03 Bckdha, Dld, Dbt
Pentose phosphate pathway (oxidative branch) 3.89E03 Pgd, Pgls, G6pd
Lipoate biosynthesis and incorporation II 1.55E02 Lipt1, Lias
Leucine degradation I 2.69E02 Bcat2, Acadm, Mccc2
Ascorbate recycling (cytosolic) 3.55E02 Glrx, Gsto1
Glutathione redox reactions II 3.55E02 Gsr, Glrx
Fatty acid b-oxidation III
(unsaturated, odd number)
3.55E02 Ehhadh, Eci1
Pentose phosphate pathway 4.07E02 Pgd, Pgls, G6pd
*IPA: ingenuity pathway analysis; BH P-value: Benjamini–Hochberg P-value.
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Dunn’s post-test for multiple comparisons was used, as appropriate
[42]. The correlation matrix was generated from Pearson’s correlations.
Data were considered significant when P < 0.05. Reported values repre-
sent the mean  SEM.
Results
Bioinformatic workflow and confirmation of
pioglitazone efficacy in the kidney and small
nerve fibres
To determine the differential effects of pioglitazone on DPN and DN and
to elucidate potential mechanisms explaining tissue-specific differences,
we compared the metabolic, neurological and renal phenotypes of db/+
and db/db mice with and without pioglitazone treatment (Fig. 1A). We
next identified differentially regulated cellular pathways using differential
analysis and SOMs to analyse RNA transcripts from the SCN, DRG, kid-
ney glomeruli and kidney cortex (Fig. 1B). Consistent with our previous
studies [20], db/db mice receiving pioglitazone treatment were signifi-
cantly heavier than both db/+ and db/db mice, but had significantly
reduced blood glucose levels and GHb % with no significant effect on
insulin, cholesterol or triglyceride levels (Fig. S1). Also consistent with
our previous study, we found that pioglitazone could significantly pre-
vent small nerve fibre dysfunction, but large nerve fibre dysfunction
was unaffected by treatment (Fig. S2). In contrast, pioglitazone had a
significant effect on DN anatomical and physiological markers of renal
function (Figs S3 and S4). Due to the positive effect of pioglitazone
treatment on hyperglycaemia, small fibre dysfunction (hind paw thermal
latency) and DN, we performed correlation analyses between these
parameters (Fig. S5; Data S1). All correlations were significant, suggest-
ing a close relationship between glycemia, small fibre dysfunction and
DN. Taken together, these data indicate that pioglitazone treatment
selectively affects different aspects of metabolism and functions in a tis-
sue-specific manner during T2DM.
Differential expression analysis of tissue-specific
RNA transcripts identifies reversed and
exacerbated genes associated with DPN, DN and
pioglitazone treatment
To identify specific mechanisms differentially affected by pioglitazone
in DPN and DN at the transcriptomic level, we first analysed steady-
state gene expression in the SCN, DRG, kidney glomeruli and kidney
cortex using RNA-Seq. This analysis resulted in an average of 29.8
(8.4) million reads, and the resulting data were subsequently anal-
ysed using differential expression analysis (Fig. 1B; Table S1). For
each type of tissue, four DEG sets were obtained from the pairwise
comparisons (db/+ versus db/db, db/+ versus db/+ PIO, db/+ PIO ver-
sus db/db PIO, and db/db versus db/db PIO) (Fig. 2A). The number of
genes regulated by diabetes (db/+ versus db/db) was similar in the
SCN (2077) and the DRG (2061); however, pioglitazone significantly
changed gene expression in 14-fold more genes in the diabetic SCN
(2368) than in the DRG (164). Similarly, in the kidney, the number of
DEGs was greater in diabetic glomeruli (1644) than in cortex (909),
and pioglitazone changed the expression of fourfold more genes in
the diabetic glomeruli (2880) than the cortex (678). These data indi-
cate that even within similar tissue, pioglitazone treatment can have
differing effects.
To better understand the cellular mechanisms driving DN and DPN
changes in response to pioglitazone treatment, we next compared db/+
versus db/db and db/db versus db/db pioglitazone DEG sets in each tis-
sue (Fig. 2B). Overall, 897 (43%) SCN DEGs and 1119 (68%) glomeruli
DEGs were significantly affected by both diabetes and pioglitazone in
db/db mice (Tables S2–S9). However, only 109 (5%) DRG and 155
(17%) kidney cortex DEGs were affected by treatment. To address the
discrepancy, we examined the transcript expression of Ppara, Ppard
and Pparg in the SCN, DRG, kidney glomeruli and kidney cortex
(Fig. S6). Pioglitazone is a PPARG agonist; therefore, we suggested that
the low number of genes regulated by pioglitazone treatment in DRG
and cortex could be due to low PPAR expression in these tissue types.
Overall, the number of Ppar transcripts was highest in kidney glomeruli
and SCN with reduced expression in the kidney cortex and negligible
transcript expression in the DRG. Hence, the reduced Ppar expression
in the DRG and the kidney cortex likely explains the relatively low num-
bers of shared DEGs in these tissues. Our subsequent analyses there-
fore focused primarily on the SCN and glomeruli, as these tissues are
affected by pioglitazone treatment.
We next determined whether DEGs shared between the db/+ ver-
sus db/db, and db/db versus db/db PIO DEG sets were regulated in
the opposite (reversed) or same (exacerbated) direction (Fig. 2C).
As large fibre dysfunction is unaffected by pioglitazone treatment in
db/db mice (Fig. S2), we reasoned that DEGs in SCN that are signifi-
cantly up-regulated during diabetes but not reversed by pioglitazone
treatment (Table S2) may contribute to large fibre dysfunction. In
contrast, genes reversed by pioglitazone treatment in the SCN
(Table S7) and reversed in the glomeruli (Table S8) may prevent
damage of the small nerve fibres and the kidney during T2DM. Con-
sistent with our phenotypic data, only half of the shared DEGs in
Fig. 2 Differential expression analysis. RNA-Seq data were used to determine gene expression in nerve (SCN, DRG) and kidney (Glom, cortex) tis-
sues from all groups. (A) Differential gene expression analysis was determined using Cuffdiff with a false discovery rate (FDR) cut-off of <0.05.
Pairwise comparisons were performed between DEG sets for all groups within a tissue. DEGs regulated by both diabetes and pioglitazone within a
tissue were determined (db/+ versus db/db and db/db versus db/db PIO). Venn diagrams illustrate the shared and unique DEGs between the two
groups. (B) Directionality of regulation of these overlapping DEG sets was assessed, and the shared genes were divided into two groups: DEGs Rev-
ersed by PIO and DEGs Exacerbated by PIO. (C) The percentage of shared DEGs exacerbated and reversed by PIO is indicated in the pie chart for
each tissue. SCN, sciatic nerve; DRG, dorsal root ganglia; Glom, glomeruli.
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SCN (49%) were reversed by pioglitazone treatment while the
majority of the shared DEGs in glomeruli (95%) were reversed.
These data suggest that pioglitazone may contribute to large nerve
fibre dysfunction by exacerbating a tissue-specific subset of genes
within the SCN while ameliorating DN via a completely different
mechanism.
Comparison of pathways using differential
expression analysis identifies cellular pathways
associated with tissue-specific pioglitazone
function
We next used the DEGs found in the SCN and kidney glomeruli to
determine which cellular pathways are associated with DPN, DN and
pioglitazone treatment. DN phenotypes were completely prevented by
pioglitazone (Fig. S3), while the effects of pioglitazone on DPN were
limited to small fibre function (Figs S1 and S2). Therefore, to identify
unique pathways underlying these tissue-specific differences, we
compared the three DEG subsets from SCN that were either (A) not
affected by pioglitazone in diabetic mice (SCN db/db only), (B) exac-
erbated by pioglitazone (SCN Exacerbated) or (C) reversed by piogli-
tazone (SCN Reversed), to DEGs reversed by pioglitazone in the
kidney glomeruli (Glom Reversed; Fig. 3A-C). This was done to iden-
tify pathways associated with large fibre dysfunction, small fibre dys-
function and DN. DEGs shared between the SCN db/db only and the
Glom Reversed sets are genes that may drive large fibre dysfunction
(Fig. 3A); there were a total of 117 DEGs shared between these two
data sets. DEGs shared between the SCN Exacerbated and the Glom
Reversed data sets indicate genes that may drive both DPN and DN
but are not reversed in the SCN by pioglitazone (Fig. 3B); there were
71 shared DEGs in the data sets. Finally, shared DEGs between the
SCN Reversed and the Glom Reversed data sets indicate genes that
are reversed in both tissues by pioglitazone. As small fibre dysfunc-
tion is prevented by pioglitazone, overlapping DEGs in this data set
may therefore contribute to small fibre dysfunction (Fig. 3C). The
SCN Reversed and Glom Reversed data set was comprised of 62
DEGs; the top 20 up- and down-regulated shared DEGs for each of
the three comparisons are listed in Tables S10–S15.
In both the SCN db/db only versus Glom Reversed (Fig. 3A) and
SCN Reversed versus Glom Reversed (Fig. 3C) DEG comparisons,
our functional analysis using DAVID identified enriched pathways
related to extracellular matrix (ECM) remodelling and focal adhesion
(Fig. 3D). In the SCN db/db only versus Glom Reversed data sets, we
found gene expression changes in collagen, type I, alpha 1 (Col1a1),
SRC kinase signalling inhibitor 1 (Srcin1) and Spon2, suggesting that
these DEGs may be involved in DN and large fibre dysfunction in DPN
(Table S11). In contrast, pioglitazone reversed expression of several
DEGs in both the SCN and the kidney glomeruli (SCN Reversed ver-
sus Glom Reversed). Bone morphogenetic protein 3 (Bmp3), laminin,
gamma 2 (Lamc2), type VI, alpha 1 collagen (Col6a1), and type III,
alpha 1 collagen (Col3a1) were reversed in both tissue types suggest-
ing that the associated pathways may be involved in DN and DPN
small fibre dysfunction (Table S15). Together, these data suggest that
correcting changes related to tissue remodelling in the glomeruli has
a large impact on DN, but the associated pathways have a more com-
plex relationship with regard to the SCN and DPN.
Of particular interest were the differential effects of pioglitazone in
nerve and kidney seen in the SCN db/db only versus Glom Reversed
(Fig. 3A) and SCN Exacerbated versus Glom Reversed comparisons
(Fig. 3B; Tables S10-S13), as these pathways may contribute to the
pathogenesis of both DPN and DN (pioglitazone treatment had no
effect on large fibre DPN but reversed DN). Among the shared DEGs,
there was functional enrichment of multiple categories related to cell
death and the inflammatory response (Fig. 3D).
Identification of dysregulated molecular
pathways associated with pioglitazone treatment
in the SCN and glomeruli using self-organizing
map analysis
Previous studies have shown that the use of differential expres-
sion analysis for analysing RNA transcripts can produce very dif-
ferent results depending on a number of factors [25]. To
support the results generated using differential expression analy-
sis, we utilized SOM analysis to identify similar patterns of gene
expression across the three experimental groups (db/+, db/db
and db/db PIO) in both the SCN and the kidney glomeruli. After
removal of very low expression values, 15,588 genes remained
for SOM analysis. Genes with similar expression patterns were
grouped into modules and plotted as a 7 9 7 map to empirically
identify biologically meaningful pathways (Fig. 4A). Genes with
the most variation across the experimental groups are gathered
in the modules in the top left and bottom right corners of the
grid map, whereas genes with less variation across groups are
gathered around the centre of the map. As a screen to identify
modules of interest, we performed DAVID for all 49 modules and
determined the most over-represented biological functions
(Fig. S7). By combining adjacent modules with similar expression
patterns, we were able to define functional clusters of interest
and identify pathways associated with diabetic complications and
pioglitazone treatment (Table 1; Fig. 4B).
The regulation pattern of genes in modules 42 and 49 is analo-
gous to the differential expression analysis of genes in the SCN Rev-
ersed and Glom Reversed groups and represents conserved
pathways that may drive both DN and small nerve fibre dysfunction
(Fig. 3C). This cluster contained pathways related to mitochondrial
dysfunction, oxidative phosphorylation, glycolysis, fatty acid b-oxida-
tion and the TCA cycle (Table 1). Genes of interest that were reversed
included those encoding subunits of the mitochondrial complexes
(complex I NADH oxidoreductase, Ndufa4/12, Ndufb3/4/6//9/10,
Ndufv1/3; complex II, Sdha, Sdhb; complex IV, Cox4i1, Cox5a,
Cox6a1, Cox6b1, Cox6c, Cox7a2, Cox7b; and complex V, Atp5g3,
Atp5b, Atpaf2), and b-oxidation enzymes (Acaa2, Echs1). Notably,
although these pathways are conserved across the tissues, they are
largely opposite in their directionality of regulation (Fig. 4B). Selected
genes in the cluster were validated in SCN and glomeruli using
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RT-qPCR, which demonstrated comparable profiles to the RNA-Seq
data (Table S16). Collectively, these observations highlight tissue-
specific pathways associated not only with diabetes pathogenesis but
with pioglitazone treatment.
Discussion
Available treatments for DPN and DN can have variable efficacy in small
nerve fibres, large nerve fibres and kidneys, suggesting that tissue-
Fig. 3 Analysis of DEGs between SCN and glomeruli. The DEG sets were analysed between the DEGs reversed by pioglitazone treatment in glomeruli
and three groups of DEGs in SCN: (A) SCN db/db only, (B) SCN Exacerbated and (C) SCN Reversed. (D) DAVID functional enrichment analysis was
performed on the shared DEGs from each comparison. Over-represented functions are shown in the heat map with P-value <0.05.
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specific mechanisms occur in response to treatment. We recently
reported that pioglitazone, a triglyceride-lowering, insulin-sensitizing
PPARG agonist, has differing effects on DPN and DN phenotypes in a
mouse model of diabetes [20]. The goal of this study was therefore to
elucidate the shared and unique mechanisms underlying DN and DPN
in response to pioglitazone treatment. Using the same experimental
paradigm as our previous study, we confirmed our previous observa-
tions that pioglitazone prevents small nerve fibre and renal dysfunction
but is unable to prevent large nerve fibre dysfunction during DPN. We
then used RNA-Seq combined with a combination of differential
expression analysis and SOM analysis to determine molecular path-
ways that may be driving tissue-specific differences.
We evaluated gene expression changes in the nerve and kidney of
control (db/+), diabetic (db/db) and pioglitazone-treated (db/+ PIO
and db/db PIO) mice. Differential expression analysis showed that
pioglitazone had a greater effect on SCN and kidney glomeruli gene
expression than on DRG and cortex profiles, likely due to reduced
PPAR expression in the DRG and the kidney cortex. Subsequent anal-
ysis therefore focused on SCN and kidney glomeruli. Consistent with
the phenotypic data, in the SCN, 897 shared genes were regulated by
both diabetes and pioglitazone, with approximately half of the overlap-
ping genes exacerbated and half reversed by pioglitazone. Those
reversed by pioglitazone likely contribute to the prevention of small
fibre dysfunction, while those exacerbated or unaffected by pioglita-
zone likely contribute to large fibre dysfunction. In contrast, of the
1119 shared genes altered in the kidney glomeruli during diabetes,
virtually all (95%) were reversed by pioglitazone treatment.
As small fibre dysfunction and DN correlated strongly with glycemia
(Fig. S5), gene expression reversal may be a downstream effect of pre-
venting hyperglycaemia (Fig. S1). It is unclear to what extent the changes
seen following pioglitazone treatment are due to direct PPAR inhibition
or prevention of hyperglycaemia. Therefore, while it is obvious that exac-
erbated changes in the large nerve fibre are directly due to pioglitazone
treatment, the prevention of DN and small nerve fibre dysfunction may
be partially due to prevention of hyperglycaemia. The enhanced expres-
sion of Ppar isoforms in tissue with high numbers of DEGs (Fig. S6),
however, suggests that Ppar inhibition plays a key role in the observed
changes. Further studies will be needed to determine the direct impact of
systemic metabolic changes on gene expression in the nerve and kidney.
Consistent with previous reports, genes associated with tissue
remodelling such as Grem1, Grem2 and Spon2 were significantly up-
regulated in the kidney glomeruli during diabetes but reversed by
pioglitazone (Table S8) [43, 44]. Similarly, levels of SPON2, an ECM
protein involved in innate immunity, correlate with DN severity in
T2DM patients [45]; we observed increased Spon2 levels in the dia-
betic kidney that were reversed by pioglitazone treatment. Our data
therefore suggest that changes in tissue remodelling and ECM func-
tion within kidney glomeruli are involved in DN pathophysiology but
ameliorated by pioglitazone. Many of these pathways are unaffected
or even up-regulated in the presence of pioglitazone in the SCN, how-
ever. For example, Col1a1, Srcin1 and Spon2 are reversed in glomer-
uli, but are unaffected by pioglitazone in SCN, suggesting a role for
these genes in large fibre dysfunction (Table S11).
In contrast, expression of other genes associated with tissue
remodelling such as Bmp3, Lamc2, Col6a1 and Col3a1 was reversed
in both the kidney glomeruli and the SCN in response to pioglitazone
(Table S15). This suggests a role for these genes in small fibre dys-
function. Indeed, injection of Bmp2-overexpressing fibroblasts can
promote sensory nerve remodelling and neurogenic inflammation in
C57BL/6 mice [46]. Regardless of large/small fibre stratification,
these data implicate dysfunctional ECM signalling and tissue remod-
elling as shared pathogenic mechanisms between DN and DPN.
Fig. 4 Analysis of self-organizing maps. SOM analysis was applied to the RNA-Seq data to identify coherent patterns of gene expression across six
groups: db/+, db/db and db/db PIO in SCN and glomeruli. (A) SOM clustering analysis demonstrates the distances between correlated gene groups.
Small blue hexagons represent a module containing genes with a similar expression pattern. The neighbouring modules are connected with a red
line. The colours between the modules indicate the similarity between modules: Lighter colours represent higher similarity, and darker colours repre-
sent lower similarity. (B) Gene expression patterns of biological interest were identified, and a cluster comprised of modules 42 and 49 was further
analysed.
2148 ª 2017 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
Inflammatory pathways are also differentially regulated in DPN
and DN. Mmp12, part of the inflammatory matrix metalloproteinase
family, was up-regulated in the SCN 143-fold during diabetes but
unaffected by pioglitazone treatment (Table S2), supporting our previ-
ous study which demonstrated Mmp12 up-regulation in the SCN of
leptin-deficient BTBR ob/ob mice [36]. In contrast, Mmp12 deletion in
diabetic mice reduces kidney glomeruli matrix accumulation and
markers of inflammation, suggesting an important but reversible role
for MMP12 in driving kidney complications [47].
To confirm these results, we also used SOM analysis to detect tis-
sue-specific transcription changes in the SCN and kidney glomeruli
following pioglitazone treatment. We focused on modules 42 and 49
as their shared pattern of gene expression compares genes that are
reversed by pioglitazone treatment in both the kidney glomeruli and
SCN (analogous to the Glom Reversed and SCN Reversed differential
expression analysis in Fig. 3C). This pattern offers mechanistic
insight into conserved pathways that may drive both DN and small
nerve fibre dysfunction in T2DM. Moreover, this gene cluster likely
has greater translational relevance as DPN is predominantly a small
fibre disease [6].
This SOM cluster showed enriched transcripts related to mitochon-
drial dysfunction, fatty acid b-oxidation, the TCA cycle and oxidative
phosphorylation (Table 1). These data support our previous transcrip-
tomics finding that SCN energy homeostasis is important in small fibre
neuropathy [20]. Indeed, regulation of these transcripts during diabetic
complications is consistent with previous reports demonstrating an up-
regulation of endothelial mitochondrial metabolism in response to
excess substrate [48]. However, the opposite directionality of change
(down-regulation and reversal in SCN, up-regulation and reversal in
Glom) suggests a more complex relationship with regard to substrate
metabolism in diabetic complications-prone tissues. We recognize that
additional mechanistic work is required to explore the biological rele-
vance of transcriptomics data; however, this observation parallels our
recent report of tissue-specific changes in fatty acid flux and mitochon-
drial metabolism, in vivo, in nerve and kidney in BKS-db/db mice [37].
Whether these changes in transcriptomics and fluxomics are the cause
or the result of diabetes is unknown. Indeed, cross-complications meta-
bolic reprogramming is the subject of ongoing work by our group.
Lastly, to investigate the reproducibility of our transcriptomic
studies, we identified common DEG sets shared between the current
RNA-Seq analysis and our previous microarray DEG study in the SCN
and the DRG [20] (Fig. S8A). The number of overlapping DEGs
between the studies was relatively low during diabetes (db/+ versus
db/db: 411 SCN and 241 DRG) and following pioglitazone treatment
(db/db versus db/db PIO: 1408 SCN and 392 DRG). This may reflect
differences in the animal models, the platforms or both. Also, while
our data suggest that RNA-Seq is more sensitive than microarray
when detecting DEGs (Fig. S8B), the enriched pathways detected
using both techniques were highly similar despite the relatively low
number of overlapping DEGs (Fig. S8C).
In summary, the current differential expression and SOM analyses
suggest that shared pathogenic mechanisms exist between DPN and
DN, including ECM dysfunction, tissue remodelling, inflammation and
dysfunctional mitochondrial metabolism. Our data suggest that large
fibre dysfunction may be related to inflammation, while mitochondrial
metabolism may play a greater role in small fibre pathophysiology in
T2DM. Moreover, targeting both of these pathways is likely to improve
DN phenotypes. We previously reported that lipid-targeted, insulin-
sensitizing pioglitazone therapy improved DN, and small fibre measures
of DPN. The current study extends those data to suggest that systemic
changes in metabolism in T2DM are also associated with distinct tis-
sue-specific metabolic reprogramming in kidney and nerves (similar
pathways regulated, different directionality of regulation) and that these
changes play a critical role in DN and small fibre DPN pathogenesis.
This new insight highlights the potential dangers of a ‘one size fits all’
approach to T2DM therapeutics, as the same drug may simultaneously
alleviate one complication while exacerbating another.
Our analyses therefore have the potential to enhance future treat-
ment of diabetic complications by identifying specific molecular path-
ways associated with each type of complication.
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